Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

rasagiline

rasagiline 2 mg daily for 12 months

Trial Locations (10)

19104

University of Pennsylvania, Philadelphia

38104

University of Tennessee, Memphis

52242

University of Iowa, Iowa City

55414

University of Minnesota, Minneapolis

66160

University Of Kansas Medical Center, Kansas City

68198

University of Nebraska Medical Center, Omaha

77030

The Methodist Hospital System, Houston

85018

Phoenix Neurological Institute, Phoenix

94118

California Pacific Medical Center, San Francisco

H3A 2B4

McGill University, Montreal

All Listed Sponsors
collaborator

Western ALS Study Group

UNKNOWN

lead

Yunxia Wang, MD

OTHER

NCT01232738 - Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter